Inactive Instrument

Lannett Company, Inc.

LCI

US5160122009

Lannett Company, Inc. Provides Earnings Guidance for the Fiscal Year 2021

May 05, 2021 at 07:15 pm

Lannett Company, Inc. provided earnings guidance for the fiscal year 2021. For the year, the company expects net sales to be in the range of $480 million to $500 million.

Latest news about Lannett Company, Inc.

Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	16/06/23	CI
Lannett Company, Inc. Emerged from Bankruptcy	16/06/23	CI
First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.	08/06/23	CI
First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.	05/06/23	CI
Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/05/23	CI
Motion for Joint Administration Approved for Lannett Company, Inc.	04/05/23	CI
Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.	04/05/23	CI
Global markets live: Ford, AMD, Starbucks, Estee Lauder, CVS Health....	03/05/23
Motion for Joint Administration Filed by Lannett Company, Inc.	03/05/23	CI
Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.	02/05/23	CI
Lannett Company, Inc. Filed for Bankruptcy	02/05/23	CI
Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index	25/04/23	CI
John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	14/04/23	CI
John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	14/04/23	CI
Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	04/04/23	CI
Top Premarket Gainers	02/02/23	MT
Transcript : Lannett Company, Inc., Q2 2023 Earnings Call, Feb 01, 2023	01/02/23
Earnings Flash (LCI) LANNETT COMPANY Reports Q2 Revenue $80.9M	01/02/23	MT
Earnings Flash (LCI) LANNETT COMPANY Posts Q2 Loss $-0.34	01/02/23	MT
Lannett Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	01/02/23	CI
Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022	01/02/23	CI
Lannett Company, Inc. Raises Earnings Guidance for the Fiscal Year 2023	01/02/23	CI
Lannett to Implement 1-for-4 Reverse Stock Split	26/01/23	MT
Lannett Company Provides Development Update on Biosimilar Insulin Products	04/01/23	CI
Jeffrey Farber Announces Not to Stand for the Re-Election to the Board of Lannett Company, Inc	29/11/22	CI

Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company's product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.64%	43.3B
OTSUKA HOLDINGS CO., LTD.	+21.25%	22.22B
SANDOZ GROUP AG	+18.92%	15.43B
ZYDUS LIFESCIENCES LIMITED	+53.19%	12.72B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.11%	6.71B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.68%	5.5B
GEDEON RICHTER	+6.91%	4.78B

Generic Pharmaceuticals